Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin®) treatment in follicular non-Hodgkin's lymphoma

Hellenic Journal of Nuclear Medicine

Volumn 11, Issue 1, 2008, Pages 12-15

  Otte, Andreas ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

111In; 90Y; Biodistribution; Ibritumomab tiuxetan Zevalin ; Prediagnostic imaging

Indexed keywords

IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN I 111; INDIUM 111; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TOSITUMOMAB I 131;

ADD ON THERAPY; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW; CANCER STAGING; DOSIMETRY; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG UPTAKE; FOLLICULAR LYMPHOMA; HUMAN; ISOTOPE LABELING; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTE COUNT; WHOLE BODY SCINTISCANNING;

ANTIBODIES, MONOCLONAL; DIAGNOSTIC IMAGING; HUMANS; LYMPHOMA, NON-HODGKIN; PATIENT SELECTION; PROGNOSIS; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 43249112792     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5 (10 Suppl): 3292s-3303s.
2. 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 1999; 5 (10 Suppl): 3287s-3291s.
3. 90Y-2IT-BAD-LYM-1 in patients with non-Hodgkin's lymphoma. Anticancer Res 2000; 20: 3647-3655.
4. 67Copper-2-iminothiolane-6-[p-(bromoacetamido) benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5 (10 Suppl): 3330s-3336s.
5. 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med 1999; 40: 2014-2020.
6. 211At-rituximab against non-Hodgkin's lymphoma cells. Br J Cancer 2000; 83: 1375-1379.
7. 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002; 16: 60-66.
8. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 3246-3256.
9. 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma (letter). Blood 2004; 103: 1175.
10. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43: 267-272.
11. 90Y-ibritumomab fluxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465-474.
12. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann Oncol 2005; 16: 786-792.
13. 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2007; 34: 616-622.
14. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 766-777.
15. Wiseman GA, White CA, Sparks RB et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181-194.
16. β) given as consolidation of first remission in patients with advanced-stage follicular lymphoma in the international phase 3 first-line indolent trial (FIT) (Abstr). Blood 2007; in press.
17. Karagiannis TC. Radioimmunotherapy: Principles, current trends and future directions. Hell J Nucl Med 2004; 7: 39-43.
18. Spies SM. Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004; 34 (suppl. 1): 10-13.
19. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 3793-3803.
20. 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: Results from a Zevalin imaging registry. J Nucl Med 2005; 46: 1812-1818.
21. Zevalin (ibritumomab tiuxetan) prescribing information. Cambridge MA, Biogen Idec Inc, 2002.
22. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-4342.
23. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
24. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
25. Bischof Delaloye A, Dreyling M. Critical evaluation of Zevalin" (ibritumomab tiuxetan) imaging registry report (27 March 2002 - 31 March 2003). Bayer Schering Pharma AG, Berlin, Germany, on file; 1-8.